Famotidine and Mortality in Coronavirus Disease 2019.
作者信息
Sethia Rahul, Prasad Manya, Garg Pramod Kumar
机构信息
Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi, India.
Department of Clinical Research and Epidemiology, Institute of Liver and Biliary Sciences, New Delhi, India.
出版信息
Gastroenterology. 2021 Jul;161(1):361-362. doi: 10.1053/j.gastro.2020.12.045. Epub 2020 Dec 31.
Abstract
摘要
相似文献
1
Famotidine and Mortality in Coronavirus Disease 2019.法莫替丁与2019冠状病毒病死亡率
Gastroenterology. 2021 Jul;161(1):361-362. doi: 10.1053/j.gastro.2020.12.045. Epub 2020 Dec 31.
2
Famotidine and Hospitalized COVID-19 Patients: Are the Benefits True?法莫替丁与住院的新冠病毒肺炎患者：益处是真的吗？
Am J Gastroenterol. 2021 Jul 1;116(7):1561. doi: 10.14309/ajg.0000000000001217.
3
Histamine receptors and COVID-19.组胺受体与 COVID-19。
Inflamm Res. 2021 Jan;70(1):67-75. doi: 10.1007/s00011-020-01422-1. Epub 2020 Nov 18.
4
Famotidine and Coronavirus Disease 2019.法莫替丁与2019冠状病毒病
Gastroenterology. 2021 Jul;161(1):360-361. doi: 10.1053/j.gastro.2020.12.044. Epub 2020 Dec 30.
5
Use of Famotidine and Risk of Severe Course of Illness in Patients With COVID-19: A Meta-analysis.法莫替丁的使用与 COVID-19 患者重症病程风险：一项荟萃分析
Mayo Clin Proc. 2021 May;96(5):1365-1367. doi: 10.1016/j.mayocp.2021.03.001. Epub 2021 Mar 5.
6
Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series.法莫替丁在非住院 COVID-19 患者中的应用及定量症状跟踪：一项病例系列研究。
Gut. 2020 Sep;69(9):1592-1597. doi: 10.1136/gutjnl-2020-321852. Epub 2020 Jun 4.
7
In Reply-Use of Famotidine and Risk of Severe Course of Illness in Patients With COVID-19: A Meta-analysis.回复——法莫替丁的使用与新冠肺炎患者重症病程风险：一项荟萃分析。
Mayo Clin Proc. 2021 May;96(5):1367-1368. doi: 10.1016/j.mayocp.2021.03.002. Epub 2021 Mar 5.
8
Association Between Famotidine Use and Clinical Outcomes in Patients With COVID-19: Assessment of Available Evidence.法莫替丁使用与新型冠状病毒肺炎患者临床结局之间的关联：现有证据评估
Am J Gastroenterol. 2021 Apr;116(4):848-849. doi: 10.14309/ajg.0000000000001008.
9
Does Famotidine Reduce the Risk of Progression to Severe Disease, Death, and Intubation for COVID-19 Patients? A Systemic Review and Meta-Analysis.法莫替丁能否降低新冠病毒肺炎患者进展为重症疾病、死亡及插管的风险？一项系统评价与Meta分析
Dig Dis Sci. 2021 Nov;66(11):3929-3937. doi: 10.1007/s10620-021-06872-z. Epub 2021 Feb 24.
10
No evidence of clinical efficacy of famotidine for the treatment of COVID-19: a systematic review and meta-analysis.法莫替丁治疗新冠病毒病的临床疗效无证据：一项系统评价和荟萃分析。
J Infect. 2023 Feb;86(2):154-225. doi: 10.1016/j.jinf.2022.11.022. Epub 2022 Dec 1.
引用本文的文献
1
A Birds-Eye (Re)View of Acid-Suppression Drugs, COVID-19, and the Highly Variable Literature.酸抑制药物、COVID-19及高度多样化文献的鸟瞰（再审视）
Front Pharmacol. 2021 Aug 11;12:700703. doi: 10.3389/fphar.2021.700703. eCollection 2021.
Zotero 插件